Slides
Page 1
Q3 2026 Results Conference call and webcast for investors and analysts NOVEMBER 5, 2026
Page 2
2 Disclosures Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact th at are independently verifiable at the date hereof, constitute forward looking statements. Examples of such forward-looking statements include statements regarding BeOne’s research, discovery, preclinical and clinical programs, plans and timelines; BeOne’s expected data readouts, trial updates and presentations; BeOne's expectations regarding regulatory milestones, submissions and filings, and commercialization of BeOne’s medicines; the potential benefits of BeOne's drugs and drug candidates; the potential of BeOne’s products and product candidates to be best-in- class and/or first-in-class; the continued growth of BRUKINSA revenues globally; the potential patient impact and commercial reach of BeOne’s drugs and drug candidates; BeOne’s expectations regarding certain valuation allowances; BeOne’s upcoming presentations and events; and BeOne’s full year 2026 guidance. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of reg ulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitabili ty, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), as well as discussions of potenti al risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. Except where otherwise noted, all information in this presentation is as of the date of this presentation, and BeOne undertakes no duty to update such information unless required by law. This presentation and the accompanying oral presentation contain data and information obtained from third-party studies and internal company analysis of such data and information. BeOne has not independently verified the data and information obtained from these sources. Forward -looking information obtained from these sources is subject to the same qualifications noted above. This presentation is intended for the investor community only; it is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. All trademarks in this presentation are the property of their respective owners. This presentation includes U.S. generally accepted accounting principles (“GAAP”) and non -GAAP financial measures. Reconciliations between these two measures are provided in the appendix to this presentation. Some of the clinical data in this presentation relating to BeOne’s investigational drug candidates is from preclinical studies or early phase, single -arm clinical trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentatio n and discussion are not based on head-to-head trials between BeOne’s investigational drug candidates and other products unless specified in the trial protocol. BeOne is still conducting preclini cal studies and clinical trials and, as additional patients are enrolled and evaluated, data on BeOne’s investigational drug candidates may change. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution. Safety and efficacy have not been established for unapproved products or uses.
Page 3
3 Agenda Welcome, safe harbor, and agenda1 Dan Maller Head of Investor Relations CEO business update2 John V. Oyler Co-Founder, Chairman and CEO Financial results3 Aaron Rosenberg Chief Financial Officer R&D and pipeline progress4 Lai Wang, Ph.D. President and Global Head of R&D Q&A5 BeOne management team
Page 4
4 CEO business update John V. Oyler Co-Founder, Chairman and CEO
Page 5
5 % change represents Q3 2026 vs. Q3 2025 1 Diluted earnings per ADS is presented. Basic earnings per ADS for Q3 2026 was $3.38 (GAAP) and $4.74 (non -GAAP) 2 Non-GAAP earnings per ADS is a financial measure that excludes from the corresponding GAAP measure costs related to share -based compensation, impairment of equity investments, depreciation and amortization expense. A reconciliation of this non -GAAP measure to the comparable GAAP measure for Q3 2026 is i ncluded in the Appendix to this presentation 3 Free cash flow is a financial measure of cash flow that deducts capital expenditures from cash flows from operations. A recon ciliation of this non-GAAP measure to the comparable GAAP measure is included in the Appendix to this presentation Q3 2026: Delivering at scale. Model proven. Impact multiplying. Pipeline highlights Financial and business highlights REVENUE $1.9B +34% Y/Y EARNINGS PER ADS 1 $3.28 GAAP · Non-GAAP2 $4.59 CASH FLOW $509M Operating CF · FCF $474M (Non-GAAP)3 GUIDANCE RAISE $250M Revenue midpoint · +$200M op income HEMATOLOGY Foundational heme franchise expansion BRUKINSA 1L MCL Mangrove FDA filing acceptance (priority review) Taca-deg RR CLL Phase 2 positive readout; AA submission expected mid-2027 SOLID TUMORS 5 pivotal-stage programs advancing CDK4i Ph3 enrolling; B7-H4 ADC FSE achieved; GPC3x41BB, Ph3 by YE; PRMT5i, CEA ADC pivotal 2027 KEY DATA PRESENTATIONS ESMO recap; ASH preview 45 abstracts at ASH, including 5 orals Other highlights: BRUKINSA #1 BTKi globally BEQALZI U.S. launch RevMed collaboration
Page 6
6 Powerful and sustained BTK inhibition 139 224 270 313 351 479 504 616 563 684 739 845 761 893 1,005 73 85 88 100 137 156 186 212 229 266 302 301 334 355 386 212 309 358 413 488 635 690 828 792 950 1,041 1,146 1,095 1,248 1,391 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 % change represents Q3 2026 vs. Q3 2025 U.S. BRUKINSA approved B-cell malignancies: CLL, WM, MCL, MZL and FL Foundational BRUKINSA sustained U.S. and global leadership BRUKINSA global quarterly revenue 2023 2024 2025 2026 $ in millions #1 MARKET SHARE Sustained U.S. and global leadership +34% FASTEST GROWTH Fastest growing cBTKi 5 BROADEST LABE L Broadest label of BTKi; MANGROVE unlocks 1L MCL opportunity 330k+ PATIENTS TREATED Across 80+ markets Ex-U.S. U.S.
Page 7
7 ENDPOINT COMPARATOR DATASET (n) aHR (95% CI) Overall survival Acalabrutinib Medicare FFS1 (n=7,315) 0.77 (0.66–0.88) Acalabrutinib Komodo2 (n=16,788) 0.75 (0.65–0.86) Acalabrutinib PurpleLab CLEAR3 (n=15,316) 0.75 (0.67–0.84) Acalabrutinib Optum4 (n=6,164) 0.84 (0.69–1.03) Ibrutinib Medicare FFS1 (n=6,214) 0.64 (0.54–0.77) Ibrutinib PurpleLab CLEAR3 (n=13,745) 0.68 (0.60–0.76) Ibrutinib Optum4 (n=5,853) 0.73 (0.56–0.94) Time to discontinuation/death Acalabrutinib Medicare FFS1 (n=7,315) 0.86 (0.78–0.94) Acalabrutinib Komodo2 (n=16,788) 0.86 (0.81–0.91) Acalabrutinib Optum4 (n=6,164) 0.84 (0.77–0.92) Acalabrutinib IQVIA PharMetrics5 (n=1,434) 0.76 (0.59–0.97) Acalabrutinib Italian Multicenter RWE6 (n=556) 0.27 (0.17–0.44) Ibrutinib Medicare FFS1 (n=6,214) 0.57 (0.51–0.64) Ibrutinib Optum4 (n=5,853) 0.66 (0.59–0.74) Ibrutinib IQVIA PharMetrics5 (n=1,024) 0.51 (0.39–0.66) Time to next treatment/death Acalabrutinib Medicare FFS1 (n=7,315) 0.87 (0.78–0.96) Acalabrutinib Komodo2 (n=16,788) 0.89 (0.80–0.98) Acalabrutinib Optum4 (n=6,164) 0.80 (0.69–0.93) Acalabrutinib Italian Multicenter RWE6 (n=556) 0.18 (0.11–0.30) Ibrutinib Medicare FFS1 (n=6,214) 0.63 (0.55–0.71) Ibrutinib Optum4 (n=5,853) 0.77 (0.63–0.94) Adjusted hazard ratios: BRUKINSA vs. acalabrutinib and ibrutinib Real-world evidence: BRUKINSA reported lower risk of death and treatment failure vs. acalabrutinib and ibrutinib 0.1 0.25 0.5 1 2 Acalabrutinib Ibrutinib Favors BRUKINSA Favors comparator 1 Ermann DA, et al. Oncol Ther. 2026;14:995-1010 2 Jacobs R, et al. ASCO 2026 3 Guru Murthy GS, et al. ASH 2026 4 Saba N, et al. ASH 2026 5 Saba N, et al. EHA 2026 6 Martino EA, et al. 53° Congresso Nazionale SIE; Rome, 21–23 Nov 2026 Real-world evidence is hypothesis generating; no definitive conclusions can be drawn in the absence of head -to-head clinical data Log scale. Adjustment: IPTW for Komodo, PurpleLab and Italian multicenter RWE; multivariable Cox for Medicare, Optum and IQVIA PharMetrics
Page 8
8 A BeOne medicine for each patient’s journey INDICATION TODAY FUTURE CLL Frontline CLL R/R MCL Frontline MCL R/R WM MZL / FL 1 Approved 2 Submitted for approval 3 Global registrational trial ongoing 4 Phase 1 evaluation ongoing Investigational agents and uses; safety and efficacy not established BRUKINSA + R2No BeOne option today BRUKINSA1 BRUKINSA combos3BRUKINSA1 BRUKINSA1 BEQALZI3 taca-deg3taca-deg + BEQALZI3BRUKINSA1 BRUKINSA1 BRUKINSA + BEQALZI3 taca-deg + BEQALZI4 taca-deg4BRUKINSA1 BRUKINSA1 taca-deg3 taca-deg + BEQALZI3 BEQALZI + O3BRUKINSA1 BRUKINSA1 BEQALZI1 BRUKINSA + BEQALZI3BRUKINSA1 BEQALZI1 taca-deg4 Additional Hematology assets entering clinic Asset Phase 1 FIH KAT6A/B inhibitor In clinic BAFFR×CD22×CD3 tsAb Q4 2026 CD19×CD20×CD3 tsAb Q4 2026 CD19 iγδT cell therapy 2027 Menin inhibitor 2027
Page 9
9 Solid tumor: delivering on our promise ~70% ORR with letrozole in 1L HR+/HER2- mBC2 CDK4i 0% grade ≥3 neutropenia at RP3D: differentiated heme safety in a ~$15B class 55% uORR (45% cORR) in OC at target dose levels, regardless of B7-H4 expression2 B7-H4 ADC Potential best-in-class safety (15% grade ≥3 neutropenia and 4% dose reductions) 36% cORR in 2L+ HCC, ~5x higher than standard of care with differentiated safety profile1,2 GPC3 x 4-1BB First-in-class, with a path to accelerated approval 38.5% cORR in MTAP-deficient, EGFR wild-type NSCLC1 PRMT5i Strong efficacy and brain activity (31% confirmed intracranial ORR) 60% cORR in CEA-high NSCLC1 CEA ADC Potential first-in-class CEA ADC in NSCLC 1 Presented at ESMO Congress 2026. GPC3 x 4 -1BB: Chon HJ, et al. PRMT5i: Rodón J, et al. CEA ADC: Lee M, et al. 2 ASCO 2026 company presentation Differences in study populations and trial design are not accounted for. Definitive conclusions cannot be drawn from cross -trial comparisons Investigational agents and uses; safety and efficacy not established
Page 10
10 Ovarian* 0.3 0.2 B7-H4 ADC B7-H4 (any expression) Liver (HCC)* 0.9 0.8 GPC3 × 4-1BB bsAb GPC3 (most HCC) Pivotal-stage programs are poised to exponentially change our global patient impact Lung (NSCLC†) 2.2 1.6 CEA ADC CEA-high (~30%) PRMT5i MTAP-deleted (~13%) Breast 2.4 0.7 CDK4i HR+/HER2– (~70%) Stomach/GEA 1.0 0.6 TEVIMBRA HER2+ (~15–20%) Indication Global annual cases (millions) Incidence Mortality BeOne asset Biomarker Source: GLOBOCAN 2024 (Sung et al., CA Cancer J Clin 2026; IARC/WHO); stomach derived from published shares *GLOBOCAN 2022. †NSCLC estimated as ~85% of lung cancer
Page 11
11 Our innovation engine is delivering top-tier productivity 1 Time from FIH to pivotal start for CDK4i and B7 -H4 ADC 2 Time from FIH to pivotal start for all distinct oncology NMEs entering first global registrational Phase 3 3 Distinct solid tumor oncology NMEs entering first global registrational Phase 3 within a rolling 18 -month period (counts of peak studies across peers since 2010) Sources: Citeline TrialTrove as of October 13, 2026. Start dates from CT.gov Internally discovered Externally discovered LEADING DISCOVERY PRODUCTIVITY TOP -TIER LATE -STAGE THROUGHPUTCOMPETITIVELY ADVANTAGED SPEED BeOne 20 Large Pharma 1 17 Large Pharma 2 15 Large Pharma 3 12 Biotech 1 8 Large Pharma 4 6 Large Pharma 5 6 Biotech 2 4 Biotech 3 4 Oncology NMEs entering the clinic (2024–2026 YTD) Highest count of new solid tumor NMEs entering late-stage trials (in 18-month period)3 Time from FIH to pivotal start for CDK4i and B7-H4 ADC vs. oncology average BeOne – 20261 Oncology average2 4.3 years 21 3 2.5 years BeOne* (2026-27) 5 Large Pharma 1 (2022-24) Large Pharma 2 (2024-26) 5 Large Pharma 3 (2023-24) 4 Large Pharma 4 (2012-13) 4 Large Pharma 5 (2020-21) 3 Biotech 1 (2025-26) 3 Large Pharma 6 (2025-26) 3 6 *projected
Page 12
12 A repeatable model to build the world’s leading oncology company Collectively deliver Profits reinvested Rigorous, prolific research 1 Global development superhighway 2 Global commercial presence 3 Entrepreneurial culture 4 Industry-leading R&D returns Strong financial profile OUR FOUNDATIONAL COMPETITIVE ADVANTAGES
Page 13
13 Financial results Aaron Rosenberg Chief Financial Officer
Page 14
14 Commentary • BRUKINSA: +34% - Sustained BTK leadership in the U.S. - Strong underlying demand growth while maximizing value share • TEVIMBRA: +28% - Continued China leadership - Global markets launches beginning to contribute to growth • In-licensed/other: +32% - Amgen portfolio growth of 26% Q3 2026: product revenue composition Growth % represents Q3 2026 vs. Q3 2025 Figures may not sum due to rounding Product revenue 1,041 1,146 1,095 1,248 1,391 191 182 206 229 243 164 148 186 204 216 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 BRUKINSA TEVIMBRA In-licensed / Other +33% growth 1,395 1,476 1,487 1,855 $ in millions (Q3 2026) 1,680 Cerulean blue 0, 102, 128
Page 15
15 Product revenue mix 80 234 527 1,013 ROW Europe China U.S. Product revenue growth Growth % represents Q3 2026 vs. Q3 2025 Q3 2026: diversified revenue mix and growth across all markets 58% 41% 21% 36% ROW Europe China U.S. $ in millions (Q3 2026) Growth % (Q3 2026)
Page 16
16 Q3 2026: reported financial information (GAAP) $ in millions (except per ADS) Total revenue Gross margin % Total operating expenses R&D SG&A Income from operations Net income Earnings per ADS - diluted Cash flow from operating activities Q3 2026 1,890 88% 1,254 661 593 419 385 $3.28 509 Q3 2025 1,412 86% 1,053 524 529 163 125 $1.09 403
Page 17
17 1 Adjusted income from operations and adjusted earnings per ADS are non -GAAP financial measures that exclude from the corresponding GAAP measure costs related to share-based compensation, depreciation, amortization expense, and impairment of equity investments 2 Free cash flow is a financial measure of cash flow that deducts capital expenditures from cash flows from operations A reconciliation of this non-GAAP measure to the comparable GAAP measure is included in the appendix to this presentation Q3 2026: adjusted financial information (Non-GAAP) $ in millions (except per ADS) Total revenue Gross margin % Total operating expenses R&D SG&A Adjusted income from operations1 Adjusted net income Adjusted earnings per ADS1 – diluted Free cash flow2 Q3 2026 1,890 90% 1,090 586 504 612 539 $ 4.59 474 Q3 2025 1,412 86% 880 446 434 341 304 $ 2.65 354
Page 18
18 Other considerations impacting net income and EPS: Other income (expense)1: Estimated range of $25-$50M in expense. Includes interest amortization from the Royalty Pharma arrangement Income tax outlook: Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized. Management expects the reversal will occur in the fourth quarter of 2026. See Form 10-Q for additional updates on income tax uncertainties Diluted ADS outstanding: The Company expects diluted ADSs outstanding of approximately 118M Key assumptions: Fx rates as of November 1, 2026 1 Includes impact of product mix and productivity improvements 2 Does not assume any potential new, material business development activity or unusual/non -recurring items 3 Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share -based compensation, depreciation and amortization expense. Guidance assumes that non-GAAP expenses track overall expense growth. A reconciliation of these non -GAAP measures to the comparable GAAP measure is included in the appendix to this presentation Updated full year 2026 guidance Prior FY 2026 guidance Current FY 2026 guidance Total revenue $6.6 - $6.8B $6.9 - $7.0B GAAP gross margin %1 High-80% range High-80% range GAAP operating expenses (combined R&D and SG&A)2 $4.8 - $5.0B $4.9 - $5.0B GAAP operating income2 $1.0 - $1.1B $1.2 - $1.3B Non-GAAP operating income2, 3 $1.7 - $1.8B $1.9 - $2.0B
Page 19
19 R&D and pipeline progress Lai Wang, Ph.D. President and Global Head of R&D
Page 20
20 Progress across BeOne’s growing pipeline BRUKINSA® (zanubrutinib) • U.S. (priority review), EU, and CN submissions completed for MANGROVE TN MCL; plenary presentation at ASH BEQALZI (sonrotoclax) • CELESTIAL-304 (ZS vs. AV in TN CLL) on track to complete enrollment before YE Tacabrutideg (BGB-16673) • Phase 2 in R/R CLL met primary endpoint of ORR with strong DoR, PFS and safety; potential FDA submission expected mid-2027 • CaDAnCe-302 and 304 update: modifications being made based on the growing confidence from emerging data TEVIMBRA® (tislelizumab) • HERIZON-GEA-01 1L HER2+ GEA1 approved in U.S. Pipeline update • KANDELA-302 (CDK4i in 1L HR+/HER2- BC) study sample size increases to 1,200 patients to accelerate the readout timeline • Starstone-301 (B7-H4 ADC in 1L OC maintenance) FSE achieved • GroundBBreaker-301 (GPC3 x 4-1BB bsAb in 2L+ HCC) first site initiated, FSE on track by YE • PRMT5i ODD granted by FDA for pancreatic cancer, 1L NSCLC combo with PD-1/chemo enrollment ongoing; combo with RevMed assets on track to initiate before YE • CEA ADC FTD granted by FDA for NSCLC, 1L NSCLC combo with PD-1 enrollment ongoing Hematology Solid Tumor 1 Zymeworks/Jazz collaboration Safety and efficacy have not been established for investigational products or uses
Page 21
21 1 Expected to enter the clinic in 2026 2 Expected to enter the clinic in 2027 3 DualityBio collaboration 4 Huahui Health collaboration Safety and efficacy have not been established for investigational products or uses A deep pipeline designed to deliver leadership across key disease areas Breast/ Gynecologic BCL2i (21447) B7-H4 ADC3 Claudin6 x CD3 bsAb KAT6A/Bi CDK2 CDAC CDK4i Hematology/ Oncology BTKi (BRUKINSA) Tacabrutideg BCL2i (BEQALZI) BAFFR x CD22 x CD3 tsAb1 CD19iγδT cell therapy2 CD19 x CD20 x CD3 tsAb1 KAT6A/Bi Immunology/ Inflammation IRAK4 CDAC KLRG1 mAb Tacabrutideg Gastrointestinal EGFR x MET x MET tsAb GPC3 x 4-1BB bsAb HPK1i PRMT5i PD1 x VEGF x CTLA4 tsAb4 Lung CEA ADC EGFR x MET x MET tsAb PRMT5i EGFR x MET x MET tsADC KEAP1 activator1 B7-H3 x ITGB6 bsADC1 ADAM9 ADC RAS(ON)i PD1 x VEGF x CTLA4 tsAb4 Menin inhibitor2
Page 22
22 CRBN Phase 2 in R/R CLL achieved its primary ORR endpoint, with encouraging DoR, PFS and safety; potential FDA submission targeted for mid-2027 Tacabrutideg is on track to be potential first-in-class and best-in-class BTK degrader CLINICAL PROGRESS PRECLINICAL HIGHLIGHTS 1 Productive ternary complex drives BTK degradation and inhibition When degradation is impaired, inhibitor function suppresses BTK Ub Ub Ub Taca-deg BTK 2 CRBN BTK CRBN BTK BTK ubiquitination and degradation BCR signaling suppression Taca-degTaca-deg CRBN loss or mutation BTK/CRBN interface disruption Tacabrutideg Bexobrutideg B C E L L P L A T E L E T CaDAnCE-304 (vs. pirtobrutinib) upsizing study from 500 to 600 patients to accelerate readout; still on track to complete enrollment in early 2027 CaDAnCE-302 (vs. physician’s choice) converting to a Phase 2 based on our increased confidence in 304 trial outcome Phase 3 taca-deg+sonro in R/R CLL on track to begin enrollment in 1H 2027 Excellent selectivity across kinome and protein degradation assays1 Secondary inhibitor MOA may raise the barrier to resistance and prolong response duration2 1 Wang H et al. BGB-16673 (Tacabrutideg), a potent BTK degrader in human blood and cancer cell lines, shows high selectivity in both proteomics and kinome panel analyses, SOHO 2026 2 Wang H et al. Tacabrutideg (BGB-16673) differentiates from other BTK degraders through potent intrinsic BTK inhibition that limits E3 ligase loss –driven resistance, ASH 2026 Safety and efficacy have not been established for investigational products or uses Tacabrutideg BexobrutidegTacabrutideg Bexobrutideg
Page 23
23 BGB-B2033 - GPC3 x 4-1BB bsAb FIC potential breakthrough therapy in HCC with unprecedented efficacy and safety Advancing into earlier lines Now 3L+ potentially pivotal4 cohort fully enrolled 4Q26 2L+ global Phase 3 2L+ Phase 2 potential U.S. AA 1H27 1L global Phase 3 study start 1H27 1L Phase 1b combo data disclosure U.S. cancer burden1 HCC has high unmet need, ranking 6th in U.S. cancer mortality but has few innovative therapies in development 36% confirmed ORR as monotherapy in heavily pretreated advanced HCC, with strong durability3 Differentiated, favorable safety profile without CRS as next-gen T-cell engager 1L triplet combo progressing well with strong data 1 SEER 2026, ACS. Assumes HCC Is 80% of liver cancer, AASLD 2023. Assumes 15% EGFR mutation rate in NSCLC, mortality to incidence ra tio of 0.55 2 CT.gov, excludes country/region-specific trials 3 Preliminary Ph1 data presented at ESMO 4 China or South Korea Safety and efficacy have not been established for investigational products or uses 12 25 8 25 11 53 25 27 32 34 36 68 Estimated new cases (thousands) Estimated deaths (thousands) Global Ph3 since 20212 11 2 18 9 10 20 Multiple Myeloma HCC Pancreatic cancer EGFRm NSCLC TNBC SCLC
Page 24
24 18% 12% 9% 7% 6% 6% 5% 2% 1% AST increased ALT increased IRR Platelet decreased Bilirubin increased Pyrexia Hypothyroidism Grade 1-2 Grade ≥3 -100 -80 -60 -40 -20 0 20 0 3 6 9 12 15 Target lesion change from baseline (%) Time from first treatment (months) Chon HJ, et al. Oral Presentation at ESMO 2026, 1679O; data cut -off 22 September 2026 a Investigator-assessed confirmed responders Safety and efficacy have not been established for investigational products or uses BGB-B2033 - GPC3 x 4-1BB bsAb in 2L+ HCC Favorable safety profile and durable responses consistent with immune mechanism TRAEs occurring in >5% patients DOR rate (95% CI), % 450 mg Q3W (n=9)a All patients (N=27)a 6-month 74.1 (28.9-93.0) 79.2 (56.9-90.8) Ongoing Discontinued
Page 25
25 1 Preliminary Ph1 data presented at ESMO (N=182; NSCLC n=83) Safety and efficacy have not been established for investigational products or uses BGB-58067 - PRMT5i Potential best-in-class brain-penetrant therapy with broad utility Objective responses observed in multiple MTAP- deficient tumors with intracranial responses in patients with brain metastases In pretreated MTAP deficient EGFRwt NSCLC, confirmed ORR 38.5% and mPFS 8.1 months1 Favorable safety profile with a low discontinuation rate Evaluation with PD-1/chemo ongoing in 1L NSCLC; combo with RevMed RAS inhibitors in PDAC to start before YE Broad development plans Meaningful opportunity in various MTAPdel tumors 1L, 2L, and early-stage NSCLC Pivotal studies in planning PDAC ODD granted; 1L RASi combinations under evaluation (RevMed collaboration) GBM and other tumors Generating data Proportion MTAPdel MTAPdel prevalence 270k 100k 70k NSCLC Pancreatic GBM 13% 22% 43%
Page 26
26 1 Rodon J, et al. Poster Presentation at ESMO 2026, 1043P; data cut -off 12 September 2026; N=182; NSCLC n=83 2 Reungwetwattana T, et al. J Clin Oncol. 2018:Jco2018783118 3 Tropion-Lung01 4 Best JT, et al. JCO Precis Oncol 9, e2500564(2025) Safety and efficacy have not been established for investigational products or uses; Definitive conclusions cannot be drawn from cross -trial comparisons BGB-58067 - PRMT5i Durable responses, sustained stable disease, and encouraging intracranial activity Demonstrated efficacy in brain metastasesBest overall response by investigator1 ~40% of NSCLC patients develop brain metastases The confirmed intracranial ORR was 30.8% among NSCLC patients with active brain metastases Low rate of intracranial progression of 16%, consistent with CNS penetrant osimertinib (11%) Status Ongoing Discontinued Best overall response by investigator Partial response (PR) Stable disease (SD) Progressive disease (PD) 16% 11% 37% 53% BGB-58067 Osimertinib Dato-Dxd Docetaxel CNS progression event %2 Osimertinib2 Dato-Dxd3 Docetaxel4
Page 27
27 1 Preliminary Ph1 data presented at ESMO Safety and efficacy have not been established for investigational products or uses BG-C477 - CEA ADC Potential first-in-class opportunity in NSCLC 60% confirmed ORR in heavily pretreated CEAhigh NSCLC patients, with 6 months DOR rate of 73%1 Favorable safety profile, including no grade ≥3 ILD or ocular events Combination cohort with PD-1 in 1L NSCLC ongoing 2L NSCLC Global Phase 3 in planning 1L NSCLC Generating data Early-stage NSCLC Evaluating opportunity Pathway to earlier lines of NSCLC NSCLC ~ 1/3 of NSCLC tumors have high CEA expression CEAhigh Other NSCLC
Page 28
28 0.00 0.25 0.50 0.75 1.00 0 3 6 9 12 15 18 KM plot for PFS in CEAhigh NSCLC patients (safety analysis set; N=25)× SD SD > SD × SD × PD × SD > SD × SD × PR × PR > PR > SD × PR > PR > PR × PR × PR > PR × PR > PR > PR > PR > PR × PR…-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 ᵃ One patient discontinued treatment before first post baseline scan Lee M, et al. Poster Presentation at ESMO 2026, 2567P Safety and efficacy have not been established for investigational products or uses BG-C477 - CEA ADC in late-line NSCLC Promising initial activity with durable responses Disease histology/ EGFR status Non-squamous EGFR mutant Non-squamous EGFR wild-type Squamous Treatment status > Ongoing × Discontinued Change in target lesions from baseline, % Time, months 6-month PFS rate: 76.2% (95% CI, 51.9-89.4) Events (%) 8 (32.0) Median (95%, CI) NR (6.7-NE) 25 19 15 9 4 3 0 Number at risk:Survival probability CEAhigh NSCLC EGFR wild-type (n=16) EGFR mutant (n=9) Total (n=25) Confirmed ORR n (%) 11 (68.8) 4 (44.4) 15 (60.0) DCR, n (%) 15 (93.8) 8 (88.9) 23 (92.0) CEAhigh NSCLC Censored PR > Best confirmed overall response in CEAhigh NSCLC patients (efficacy evaluable analysis set; N=24 a)
Page 29
29 What you will see at ASH 2026 45 abstracts accepted at ASH 2026 5 oral presentations, including MANGROVE plenary 32 posters BeOne to host ASH IR event on December 14, 2026 BRUKINSA First and only chemo-free option in 1L MCL1 BRUKINSA CLL patients can live as long as the general population2 BRUKINSA Higher reported real- world survival vs. acala; lowest AFib among cBTKis3 BEQALZI Deep, fixed- duration responses with no 24-hour monitoring4 TACABRUTIDEG First-in-class degrader: durable responses in pretreated CLL5 MAICs and real-world evidence are hypothesis generating; no definitive conclusions can be drawn in the absence of head -to-head clinical data 1 Wang M, et al. MANGROVE: zanubrutinib + rituximab vs. BR in TN MCL. ASH 2026 2 Munir T, et al. SEQUOIA: survival outcomes vs. a matched general population. ASH 2026 3 Guru Murthy GS, et al. Real-world OS with frontline BTKis in CLL: US multi -payer claims analysis. ASH 2026 4 Tam CS, et al. Sonrotoclax + zanubrutinib in TN CLL/SLL: ~40-month follow-up. ASH 2026. Davids MS, et al. Simplified ramp -up of sonrotoclax + zanubrutinib in TN CLL. ASH 2026 5 Allan JN, et al. Tacabrutideg in R/R CLL/SLL: CaDAnCe-101 update. ASH 2026 Safety and efficacy have not been established for investigational products or uses
Page 30
30 1 Potentially registrational Safety and efficacy have not been established for investigational products or uses Key upcoming events ✓ achieved planned Milestone H1 2026 H2 2026 2027 Hematology Phase 3 BRUKINSA+R vs. BR in 1L MCL (MANGROVE) interim analysis and submission ✓ ✓ Taca-deg Phase 2 in R/R CLL submission1 (mid-2027) Sonro Phase 3 triplet in 2L+ t(11;14) MM (CELESTIAL-305) initiation Taca-deg + sonro Phase 3 in R/R CLL (CaDAnCe-306) initiation Solid Tumors CDK4i Phase 3 in 1L HR+/HER2- (KANDELA-302) BC initiation ✓ TEVIMBRA Phase 3 in 1L HER2+ GEA U.S. approval ✓ B7-H4 ADC Phase 3 in 1L maintenance OC (Starstone-301) initiation ✓ GPC3 x 4-1BB bsAb Phase 3 in 2L+ HCC (GroundBBreaker-301) initiation GPC3 x 4-1BB bsAb Phase 2 U.S. 2L+ HCC initiation1 GPC3 x 4-1BB bsAb Phase 3 in 1L HCC (GroundBBreaker-302) initiation PRMT5i Phase 3 in NSCLC initiation CEA ADC Phase 3 in NSCLC initiation New since last update
Page 31
31 Q&A
Page 32
End
Page 33
33 Appendix
Page 34
34 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to adjusted income from operations $ in millions Q3 2026 Q3 2025 GAAP income from operations 419 163 Plus: Share-based compensation 133 141 Plus: Depreciation expense 37 36 Plus: Amortization expense 24 2 Adjusted income from operations 612 341
Page 35
35 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to adjusted income tax expense $ in millions Q3 2026 Q3 2025 GAAP income tax expense 26 22 Plus: Discrete tax items 12 1 Plus: Income tax effect of non-GAAP adjustments 28 17 Adjusted income tax expense 65 40
Page 36
36 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to adjusted net income $ in millions Q3 2026 Q3 2025 GAAP net income 385 125 Plus: Share-based compensation 133 141 Plus: Depreciation expense 37 36 Plus: Amortization expense 24 2 Plus: Impairment of equity investments - 19 Plus: Discrete tax items (12) (1) Plus: Income tax effect of non-GAAP adjustments (28) (17) Adjusted net income 539 304
Page 37
37 Reconciliation and calculation of non-GAAP financial measures Reconciliation to adjusted EPS per ADS - basic Q3 2026 Q3 2025 GAAP EPS per ADS - basic 3.38 1.13 Plus: Share-based compensation 1.17 1.28 Plus: Depreciation expense 0.33 0.32 Plus: Amortization expense 0.21 0.01 Plus: Impairment of equity investments - 0.17 Plus: Discrete tax items (0.10) (0.01) Plus: Income tax effect of non-GAAP adjustments (0.25) (0.15) Adjusted EPS per ADS - basic $4.74 $2.76 Figures may not sum due to rounding
Page 38
38 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to adjusted EPS per ADS - diluted Q3 2026 Q3 2025 GAAP EPS per ADS – diluted1 3.28 1.09 Plus: Share-based compensation 1.13 1.23 Plus: Depreciation expense 0.32 0.31 Plus: Amortization expense 0.20 0.01 Plus: Impairment of equity investments - 0.16 Plus: Discrete tax items (0.10) (0.01) Plus: Income tax effect of non-GAAP adjustments (0.24) (0.15) Adjusted EPS per ADS - diluted $4.59 $2.65
Page 39
39 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to free cash flow $ in millions Q3 2026 Q3 2025 Net cash provided by operating activities (GAAP) 509 403 Less: Purchases of property, plant and equipment (35) (48) Free cash flow 474 354
Page 40
40 Figures may not sum due to rounding Reconciliation and calculation of non-GAAP financial measures Reconciliation to non-GAAP operating income guidance for full year 2026 $ in millions GAAP Operating Income 1,200 - 1,300 Plus: Adjustments to arrive at Non-GAAP 700 - 700 Non-GAAP Operating Income 1,900 2,000
Page 41
41 Acronyms: A-I 1H First half 1L 1st-line 2H Second half 2L 2nd-line A AA Accelerated approval ADC Antibody drug conjugate ADS American depositary share AE Adverse event AML Acute myeloid leukemia AML/MDS Acute myeloid leukemia (AML) / Myelodysplastic syndromes (MDS) ASCO American Society of Clinical Oncology ASH American Society of Hematology AV Acalabrutinib + venetoclax B BC Breast cancer BCL2i BCL2 inhibitor BCLC Barcelona Clinic Liver Cancer BLA/sBLA (Supplemental) biologics license application BTKi Bruton’s tyrosine kinase inhibitor bsAb bispecific antibody bsADC Bispecific antibody drug conjugate BR Bendamustine, rituximab C cBTKi Covalent Bruton’s tyrosine kinase inhibitor CDAC Chimeric degradation activation compound CDK2 Cyclin-dependent kinase 2 CDK4i Cyclin-dependent kinase 4 inhibitor CEA Carcinoembryonic antigen cGVHD Chronic graft vs. host disease CI Confidence interval CLL Chronic lymphocytic leukemia CLL/SLL Chronic lymphocytic leukemia/Small lymphocytic leukemia CRS Cytokine release syndrome CSU Chronic spontaneous urticaria D D Diameter DCR Disease control rate DoR Duration of response E EC Endometrial cancer EHA European Hematology Association EPS Earnings per share EGFR Epidermal growth factor receptor ESMO European Society For Medical Oncology EU European Union F FD Fixed duration FDA U.S. Food and Drug Administration FIH First in human FL Follicular lymphoma FSE First subject enrolled FTD Fast Track designation FY Full year G GAAP Generally Accepted Accounting Principles GEA Gastroesophageal adenocarcinoma GI Gastrointestinal GPC3 Glypican-3 H H2H Head-to-head HCC Hepatocellular carcinoma HR Hazard ratio HR+ Hormone receptor-positive HER2+/- Human epidermal growth factor receptor 2-positive/negative I IA Interim analysis I&I Immunology and Inflammation ICML International Conference on Malignant Lymphoma IGHV / uIGHV Immunoglobulin heavy-chain variable region / unmutated IGHV IRC Independent Review Committee IV Ibrutinib + venetoclax
Page 42
42 Acronyms: J-Z PR Partial response PRMT5 / PRMT5i Protein arginine methyltransferase 5 (inhibitor) Q Q1 First quarter Q2 Second quarter Q3 Third quarter Q4 Fourth quarter R R&D Research and Development RA Rheumatoid arthritis ROW Rest of world RP2D Recommended Phase 2 dose R/R Relapsed/Refractory rwOS Real-world overall survival S SG&A Selling, General, and Administrative SLL Small lymphocytic lymphoma T TEAEs Treatment-emergent adverse events TLS Tumor lysis syndrome TN Treatment naïve TNBC Triple negative Breast cancer TN Treatment naïve tsAb trispecific antibody tsADC Trispecific antibody drug conjugate U U.S. United States V VO Venetoclax + obinutuzumab W WM Waldenström’s Macroglobulinemia X Y YE Year end Z ZS Zanubrutinib + sonrotoclax J JCO Journal of Clinical Oncology JP Japan K KM Kaplan-Meier L M mAb Monoclonal antibody MAIC Matching adjusted indirect comparison MCL Mantle cell lymphoma MM Multiple myeloma mg Milligrams MOA Mechanism of action MRD Minimal residual disease MTx Maintenance MZL Marginal zone lymphoma N NDA/sNDA (Supplemental) new drug application NE Not estimable NEJM New England Journal of Medicine NHL Non-Hodgkin lymphoma NMA Network meta analysis NME New molecular entity NSCLC Non small cell lung cancer NR Not reached O OC Ovarian cancer ODD Orphan Drug Designation ORR Objective response rate OS Overall survival P PDAC Pancreatic ductal adenocarcinoma PDUFA Prescription Drug User Fee Act PFS Progression free survival PK Pharmacokinetics p-value Probability value PoC Proof of concept